Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-300 tarlatamab in small cell lung cancer
NL-OMON54787Recruiting
- Sponsor
- Amgen
- Start
- Jul 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of tarlatamab, sponsored by Amgen. Started Jul 2019; status: recruiting.
02
Drugs
tarlatamab
Beyond the preview
Go deeper on NL-OMON54787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54787.